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Objectives: The natural history of human papillomavirus (HPV) infection has been studied extensively in young 
women; this study investigated HPV infection in adult women. 
Methods: Data from 3817 women aged 24–45 years in a global trial of the 4-valent HPV (6/11/16/18) vaccine 
were used to calculate prevalence of anogenital infections containing 9-valent (9v) HPV vaccine types (6/11/16/ 
18/31/33/45/52/58) and five non-vaccine types (35/39/51/56/59). Incidence of infections and persistent in-
fections was estimated for 989 placebo recipients naive to all 14 HPV types at baseline. Age-adjusted hazard 
ratios were calculated for various sociodemographic factors. 
Results: Prevalence of anogenital infection was highest in France at 29.2% (9vHPV types) and 21.7% (non- 
vaccine types) and lowest in the Philippines at 7.6% (9vHPV types) and 5.1% (non-vaccine types). Overall, HPV 
incidence (per 100 person-years) was 5.2 (9vHPV types) and 4.7 (non-vaccine types), and incidence of persistent 
infection was 2.7 (9vHPV types) and 2.1 (non-vaccine types). Factors associated with new HPV infections in-
cluded younger age, younger age at first intercourse, being single, current use of tobacco, and higher number of 
past and recent sex partners. 
Conclusions: Because mid-adult women acquire new HPV infections, administration of the 9vHPV vaccine could 
reduce HPV-related morbidity and mortality in this population.   
1. Introduction 
Human papillomavirus (HPV) is the commonest sexually trans-
mitted viral infection worldwide [1]. HPV infection causes most cases 
of cervical (~100%), anal (~88%), and vaginal (~78%) cancers, and 
substantial proportions of penile (~51%), vulvar (≥25%), and 
oropharyngeal (30%–70%) cancers [2–5]. HPV vaccination is an effi-
cient strategy to reduce risk of HPV-related cancers by reducing the 
pool of circulating HPV, and therefore, lessening the occurrences of 
persistent HPV infection and high-grade cancer precursor lesions. There 
are currently three licensed HPV vaccines: bivalent (2vHPV; Cervarix®, 
GSK, Rixensart, Belgium), quadrivalent (4vHPV; Gardasil®, Merck & 
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Co., Inc., Kenilworth, NJ, USA), and 9-valent (9vHPV; Gardasil 9, Merck 
& Co., Inc., Kenilworth, NJ, USA). The 4vHPV vaccine was first licensed 
in 2006 and the 2vHPV vaccine in 2009 in the United States. The 
9vHPV vaccine was first licensed in the United States in 2014 for males 
(9–15 years old) and females (9–26 years old), and in 2015 for males 
(16–26 years old) [6]. In 2018, the 9vHPV vaccine was additionally 
approved in the United States for use in men and women 27 through 45 
years old [7]. Consequently, in 2019 the Advisory Committee on Im-
munization Practices (ACIP) of the US Centers for Disease Control and 
Prevention (CDC) updated its recommendations to include catch-up 
HPV vaccination for all persons through age 26 [8]. In addition, 
recognizing that some mid-adults who were not previously adequately 
vaccinated may benefit, the ACIP recommended shared clinical decision 
making for vaccination of adults 27–45 years old [8]. 
All three licensed HPV vaccines target HPV 16 and 18, which cause 
approximately 70% of cervical cancers worldwide. The 4vHPV and 
9vHPV vaccines also target HPV 6 and 11, which cause approximately 
90% of anogenital warts, as well as a rare respiratory condition (re-
current respiratory papillomatosis) [9,10]. The 9vHPV vaccine ad-
ditionally protects against five other frequently detected high-risk HPV 
types (31/33/45/52/58) [11,12], thereby increasing coverage against 
HPV types that cause approximately 90% of cervical cancer cases 
worldwide [12,13]. Some high-risk types, such as 35/39/51/56/59, are 
not included in currently licenced HPV vaccines and are attributed to a 
smaller proportion of cervical cancers worldwide [11,14]. 
In addition to cancer protection, HPV vaccines also protect against 
low- and high-grade cervical intraepithelial neoplasia grades 1 through 
3 (CIN1, CIN2, CIN3) caused by the vaccine types. CIN2 and CIN3 are 
potential precursors to cervical cancer and represent a substantial dis-
ease burden in young and adult women worldwide. For example, the 
CDC estimates that approximately 196,000 cases of CIN2, CIN3 and 
adenocarcinoma in situ (AIS) (collectively referred to as “CIN2+”) were 
diagnosed in 2016 in the United States [15]. Approximately 76% 
(150,000) of the CIN2+ cases were attributable to 9vHPV types and 
97,000 of these cases were diagnosed in women aged 30 years or older 
[15]. 
Since licensure, the 9vHPV vaccine has been incorporated into 
standard immunization schedules in many countries, including 
Australia, Austria, Canada, Germany, and the United States [16–19]. 
The 2vHPV and 4vHPV vaccines also continue to be used in many parts 
of the world. 
HPV vaccination prior to sexual debut offers the greatest benefit for 
prevention of HPV infection and HPV-related cancers. HPV im-
munization programs therefore generally target adolescents (aged 
11–13 years, varying by country). In addition, some countries have 
established multiple age-cohort (i.e., “catch-up”) vaccination programs 
for teens and young women who are older than the targeted adolescent 
age range. Observational studies using real-world evidence have 
demonstrated the impact of HPV vaccination on genital HPV infection, 
anogenital warts, and histologically-confirmed high-grade cervical in-
traepithelial neoplasia (CIN2+) in sexually active young women, par-
ticularly in settings of high vaccine coverage (> 50% of population) 
and catch-up vaccination programs [20,21]. 
The International Agency for Research on Cancer (IARC) 
highlighted the need for HPV studies in older women and their male 
counterparts, including cohort studies with repeated measures that 
assess sexual practices and immunity [22]. A focus on adult women is 
therefore relevant to individuals up to age 45 years who were never 
vaccinated against HPV, as well as those who remain susceptible to the 
9vHPV types that are not covered in the 2vHPV or 4vHPV vaccines. 
Data on the natural history of HPV infection in older women have the 
potential to inform existing HPV prevention guidelines by shedding 
light on prevalence, incidence, and persistence of HPV infections 
among women who are typically not targeted for HPV immunization. In 
addition, pre-vaccine-era measures of the burden of HPV infection are 
important to provide context for interpreting real-world evidence of the 
impact of the vaccine [22]. For example, HPV prevalence generally 
declines with age, but in some parts of the world, a second peak of 
infection is observed in middle-aged women [23,24]. Factors such as 
these are important to understand when comparing disease burden in 
the vaccine era to that in the pre-vaccine era [23,25–28]. 
Using data from a global 4vHPV vaccine clinical trial in adult 
women (aged 24–45 years), we addressed the following objectives: (1) 
determining country-specific prevalence of anogenital infection con-
taining 14 of the most common HPV types; (2) calculating incidence of 
HPV anogenital infections and incidence of persistent infection among 
women in the placebo group who were HPV-naive at the start of the 
trial; and (3) detailing factors associated with incident HPV infection. 
Analyses focus on prevalence and incidence of 9vHPV vaccine types (6/ 
11/16/18/31/33/45/52/58), 4vHPV vaccine types (6/11/16/18), the 
contribution to prevalence and incidence of five additional types cov-
ered in the 9vHPV vaccine (31/33/45/52/58), as well as five other 
high-risk HPV genotypes for which data are available (35/39/51/56/ 
59). 
2. Materials and methods 
Data in this report are from a randomized, double-blind, placebo- 
controlled clinical trial of the safety, immunogenicity, and efficacy of 
4vHPV vaccine in adult women aged 24 to 45 years (NCT00090220). 
Trial methods, inclusion and exclusion criteria, and participant char-
acteristics have been described [29]. Briefly, between June 2004 and 
April 2005, 3819 women aged 24 to 45 years were randomly assigned 
to either 4vHPV (n = 1911) or placebo (n = 1908). Healthy, non- 
pregnant adult women with no history of anogenital warts, vulvar in-
traepithelial neoplasia, or vaginal intraepithelial neoplasia were en-
rolled from 38 study sites in seven countries (Colombia, France, Ger-
many, Philippines, Spain, Thailand, United States). 
Baseline characteristics in the trial population were generally 
similar between the vaccination and placebo arms of the trial and our 
analysis cohort. Approximately 14% of the cohort was from North 
America, 42% from Latin America, 13% from Europe, and 31% from the 
Asia/Pacific region. Mean age at baseline was 34 years, mean age at 
first sexual experience was 19 years, and 78% were married or in a 
permanent relationship. More than 90% reported no new sexual part-
ners in the 6 months before enrollment, and the median number of 
lifetime sex partners was 2, with an interquartile range of 1 to 4 [29]. 
On day 1 and at months 7, 12, 18, 24, 30, 36, 42, and 48, an endo/ 
ectocervical swab and a combined labial/vulvar/perianal swab (herein 
collectively referred to as an anogenital swab) were collected from all 
participants. A polymerase chain reaction (PCR)–based assay was used 
to test HPV DNA in the anogenital swab samples [30,31]. The assay 
included 14 HPV types: vaccine types 6, 11, 16, 18, 31, 33, 45, 52, and 
58, and five additional HPV types not included in these vaccines (35, 
39, 51, 56, and 59). 
In the present analysis, prevalent, genotype-specific HPV infections 
were calculated from baseline data from all women (vaccinated and 
control group). The prevalence of type-specific infection was defined as 
the number of women who tested positive by PCR for a given HPV 
genotype in a day 1 anogenital swab, divided by the number of women 
Abbreviations  
2vHPV bivalent HPV vaccine 
4vHPV quadrivalent HPV vaccine 
9vHPV nonavalent HPV vaccine 
CIN cervical intraepithelial neoplasia 
HPV human papillomavirus 
IARC International Agency for Research on Cancer 
PCR polymerase chain reaction   
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who had a valid day 1 HPV test for that HPV type. For variables de-
scribing combinations of HPV types, a woman was considered infected 
if at least one HPV type in the combination was detected (e.g. HPV 31/ 
33/45/52/58 means that a woman could have an infection with type 31 
and/or 33 and/or 45 and/or 52 and/or 58). More than 99% of ran-
domly assigned women had complete baseline data that were suitable 
for our prevalence analyses. 
Analyses of incident and incident-persistent HPV infections were 
based on data from women who were randomly assigned to the placebo 
arm of the trial. Incident infection with a given HPV type was defined as 
a new detection (i.e. starting at month 6 or thereafter) of HPV by PCR in 
anogenital swabs collected among women who (1) had normal Pap test 
results at baseline; (2) were naive at day 1 to the 4vHPV vaccine types 
in serum (6, 11, 16, 18); and (3) were naive at day 1 to all 14 HPV types 
measured in swabs (6, 11, 16, 18, 31, 33, 45, 52, 58, 35, 39, 51, 56, 59). 
Incident persistent infections were defined as detection of a new HPV 
genital infection by PCR in anogenital swabs collected on at least two 
consecutive visits spaced 6 months apart ( ± 4-week window). Age- 
adjusted Cox proportional hazard models were used to estimate the risk 
of incident infection associated with selected baseline characteristics. 
3. Results 
The prevalence of HPV infection varied with geographic region and 
by age of the trial participants (Table 1, Supplemental Tables 1 and 2). 
Prevalence of HPV infection with any of the 9vHPV vaccine types was 
16.4% overall, ranging from 7.6% (Philippines) to 29.2% (France) 
among adult women. The global prevalence of any 9vHPV type was 
higher among women aged 24 to 34 (20.0%) than among women aged 
34 to 45 (12.7%). The magnitude of age-related differences in infection 
prevalence also varied by country. For example, in Colombia, 9vHPV 
type prevalence was 24.3% and 14.7% among women ages 24 to 34 and 
35 to 45 years, respectively, but in the Philippines, corresponding 
prevalence in the 2 age groups was nearly identical: 7.7% and 7.6%. 
Prevalence of HPV 6/11 was 2.1% overall, ranging from 0.6% in 
Thai women to 6.7% in French women. Likewise, prevalence of HPV 
16/18 was 6.2% overall, ranging from 2.0% in the Philippines to 11.5% 
in France. Although HPV 16/18 prevalence was typically higher in 
women aged 24 to 34 years at enrollment, infections were also observed 
in women aged 35 to 45. For example, HPV 16/18 prevalence was 
9.5%, 7.8%, 6.7%, and 6.3% among women aged 35 to 45 in France, 
Germany, United States, and Spain, respectively. Prevalence of infec-
tion with the other five HPV types targeted by the 9vHPV vaccine (31/ 
33/45/52/58) was 10.7% overall, with similar geographic differences 
as observed for other HPV types. The prevalence of non-vaccine HPV 
types (35/39/51/56/59) was 14.0%, also with patterns similar to the 
9vHPV types, except in Spain, where the older women (aged 35–45 
years) had higher prevalence than the younger women (aged 24–34 
years). 
Table 2 summarizes relationships between baseline factors and the 
risk of incident (new) 9vHPV anogenital infection among women in the 
placebo group who were HPV naive at baseline. Relative to women 
aged 24 to 29 years, older women had lower risk of HPV infection, with 
women aged 40 to 45 years having approximately 45% to 48% lower 
risk of infection. Similarly, as age at first intercourse increased, in-
cidence of high-risk infections decreased. Women who were not in their 
first marriage at the time of enrollment had significantly elevated risk 
of incident HPV infection, as did women who tested positive for chla-
mydia or gonorrhea at baseline. Infection risk also increased with the 
number of lifetime sex partners and the number of new sex partners in 
the 6-month period before enrollment. Relative to current smokers, 
former and never smokers had lower risk of incident infection. 
Among the HPV-naive placebo recipients, incidence (per 100 
person-years) of anogenital infection was 5.22 (95% confidence interval 
[CI], 4.51–6.02) for any 9vHPV type, 3.07 (95% CI, 2.54–3.69) for any 
4vHPV type, 2.72 (95% CI, 2.22–3.30) for HPV 31/33/45/52/58, and 
4.72 (95% CI, 4.04–5.47) for non-vaccine types 35/39/51/56/59 
(Table 3). Approximately half the incident infections persisted 6 or 
more months as follows: 54% (9vHPV types), 56% (4vHPV types), 46% 
(types 31/33/45/52/58), and 46% (non-vaccine types 35/39/51/56/ 
59). Incidence was higher in younger women (aged 24–34 years) than 
in older women (aged 35–45 years) (Supplemental Table 3). For ex-
ample, 9vHPV type incident infection rates (per 100 person-years) were 
6.96 (95% CI, 5.76–8.32) in women aged 24–34 and 3.75 (95% CI, 
2.94–4.72) in women aged 35–45. The 48-month cumulative incidence 
of anogenital infection was 19.4% (9vHPV types), 11.8% (4vHPV types) 
and 10.5% (HPV 31/33/45/52/58) (Fig. 1a), and for persistent infec-
tions, the cumulative incidence was 10.2% (9vHPV types), 6.8% 
Table 1 
Baseline prevalence of anogenital HPV infection in 3817 women aged 24 to 45 years, by country.           
HPV type Total Colombia France Germany Philippines Spain Thailand United States 
N = 3817 N = 1610 N = 106 N = 310 N = 400 N = 65 N = 782 N = 544 
% % % % % % % %  
6 1.9 1.8 6.7 4.6 0.8 3.1 0.3 2.6 
11 0.2 0.3 0.0 0.7 0.0 0.0 0.4 0.0 
16 4.5 4.9 9.6 7.8 1.8 4.8 1.8 6.4 
18 2.1 2.2 1.9 3.3 0.8 1.6 0.6 4.3 
31 2.8 3.2 8.7 5.6 0.8 7.9 0.8 2.6 
33 0.7 0.8 1.9 1.0 0.0 0.0 0.8 0.7 
35 1.3 2.0 1.0 0.3 0.3 1.6 0.1 2.4 
39 3.0 3.4 2.9 2.6 0.8 1.6 2.3 4.8 
45 1.7 1.9 1.0 2.3 1.3 4.8 0.4 3.0 
51 3.8 4.1 9.6 5.9 1.8 4.8 1.8 4.5 
52 4.5 5.1 9.6 3.6 2.6 3.2 3.9 5.0 
56 6.4 8.0 8.7 10.5 2.0 14.3 1.4 8.2 
58 2.7 4.3 1.9 2.3 0.8 0.0 1.2 2.0 
59 2.2 2.5 5.8 3.3 1.3 0.0 1.0 2.8 
6/11 2.1 2.1 6.7 4.6 0.8 3.1 0.6 2.6 
16/18 6.2 6.8 11.5 10.1 2.0 6.5 2.3 9.9 
6/11/16/18 7.9 8.6 15.4 13.7 2.8 8.1 3.0 12.0 
31/33/45/52/58 10.7 13.1 19.0 12.4 5.1 11.5 6.1 12.0 
35/39/51/56/59 14.0 16.9 21.7 17.7 5.1 19.0 5.7 19.5 
6/11/16/18/31/33/45/52/58 16.4 19.3 29.2 20.9 7.6 15.0 8.6 20.5 
“HPV”: human papillomavirus.  
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(4vHPV types), and 4.4% (HPV 31/33/45/52/58) (Fig. 1b). 
Only a single HPV type was found in most infections, irrespective of 
whether infections were prevalent at baseline or newly acquired during 
the trial (Fig. 2; Supplemental Table 4). Approximately 69% of infec-
tions that were prevalent at baseline contained a single HPV type, 
whereas an even greater proportion of single HPV-type infections were 
found in incident (88%) and incident-persistent (approximately 93%) 
infections. 
4. Discussion 
Using data from a large clinical trial, this analysis shows that 
women aged 24 to 45 years (an age group rarely targeted for HPV 
immunization) are at risk for acquiring new HPV infections, including 
infections with HPV types targeted by the 9vHPV vaccine. In addition, 
these infections can persist for 6 or more months. Among women in the 
placebo group who were HPV-naive at baseline, new 9vHPV-type in-
fections and incident-persistent infections were identified in 19.4% and 
10.2% of the women, respectively, during the 48-month trial. Because 
some persistent infections can lead to CIN2+ and invasive cervical 
cancer, these findings suggest that infections acquired during adult 
years can be an important contributor to the cervical disease burden in 
adult women. 
Cervical screening can detect CIN2+ and treatment of CIN2+ can 
prevent progression to invasive cervical cancer. In the United States as 
of 2016, approximately 81% of women 21–65 years old up to date with 
guidelines-recommended cervical screening [32]. Based on incidence 
rates of CIN2+ established from cervical screening in the United States, 
the CDC estimates that approximately 196,000 CIN2+ cases were di-
agnosed in the United States in 2016, of which 97,000 were attributable 
to 9vHPV types and were diagnosed in women aged 30 years or older 
[15,33]. The proportion of these CIN2+ cases that was caused by HPV 
infections acquired prior to age 27 is not known. However, rates of 
progression from infection to high-grade lesions are similar in young 
and adult women, and most infections clear or progress within 1 to 3 
years [34,35], suggesting that infections acquired during the adult 
years can lead to high-grade lesions. 
Our findings of the prevalence of HPV 6/11/16/18 at baseline are 
Table 2 
Association between selected baseline characteristics and incident anogenital HPV infection in women aged 24 to 45 years.      
Baseline characteristics Age-adjusted hazard ratio (95% CI) for incident HPV DNA infection 
HPV 16/18 HPV 31/33/45/52/58, not 16/18 HPV 16/18/31/33/45/52/58  
Age, years 
24–29 (n = 250) 1.00 1.00 1.00 
30–34 (n = 223) 0.93 (0.53–1.63) 0.72 (0.41–1.24) 0.83 (0.55–1.26) 
35–39 (n = 231) 0.39 (0.19–0.81) 0.64 (0.37–1.11) 0.58 (0.37–0.91) 
40–45 (n = 285) 0.56 (0.30–1.02) 0.52 (0.30–0.91) 0.55 (0.36–0.85) 
Marital status 
Married, first marriage (n = 512) 1.00 1.00 1.00 
All others (n = 477) 1.80 (1.12–2.91) 1.43 (0.94–2.18) 1.48 (1.07–2.05) 
Regiona 
North America (n = 101) 1.00 1.00 1.00 
Europe (n = 119) 1.17 (0.42–3.29) 0.46 (0.19–1.12) 0.60 (0.30–1.18) 
Latin America (n = 387) 2.39 (1.02–5.60) 1.18 (0.64–2.16) 1.43 (0.87–2.34) 
Asia (n = 382) 0.61 (0.23, 1.62) 0.36 (0.18, 0.74) 0.42 (0.23–0.74) 
Race/Ethnicity 
White (n = 189) 1.00 1.00 1.00 
Black (n = 16) N/A (N/A) 3.23 (1.08–9.67) 1.80 (0.63–5.13) 
Hispanic (n = 398) 1.93 (1.06–3.52) 1.86 (1.06–3.25) 1.87 (1.22–2.86) 
Asia/Pacific (n = 386) 0.54 (0.26–1.14) 0.62 (0.32–1.20) 0.60 (0.36–0.99) 
Smoking status 
Current (n = 129) 1.00 1.00 1.00 
Former (n = 63) 0.69 (0.22–2.11) 0.20 (0.05–0.84) 0.33 (0.13–0.85) 
Never (n = 797) 0.74 (0.40–1.34) 0.53 (0.33–0.87) 0.61 (0.41–0.90) 
Age at first intercourse, years 
≤17 (n = 332) 1.00 1.00 1.00 
18-19 (n = 251) 0.98 (0.58–1.66) 0.86 (0.53–1.37) 0.88 (0.61–1.28) 
20-22 (n = 206) 0.68 (0.36–1.26) 0.54 (0.30–0.98) 0.63 (0.41–0.98) 
≥23 (n = 199) 0.21 (0.08–0.61) 0.27 (0.12–0.61) 0.26 (0.14–0.49) 
Lifetime number of sex partners 
1 (n = 515) 1.00 1.00 1.00 
2–3 (n = 286) 1.58 (0.93–2.69) 2.23 (1.34–3.71) 1.85 (1.27–2.71) 
≥4 (n = 186) 1.90 (1.08–3.34) 3.52 (2.12–5.85) 2.66 (1.80–3.92) 
Number of new sex partners in last 6 months 
0 (n = 936) 1.00 1.00 1.00 
1 (n = 47) 1.73 (0.79–3.79) 1.96 (0.98–3.94) 2.05 (1.20–3.51) 
2–3 (n = 2) 6.37 (0.88–46.29) 6.22 (0.85–45.23) 3.47 (0.48–25.02) 
≥4 (n = 1) N/A (N/A) N/A (N/A) N/A (N/A) 
Number of prior pregnancies 
0 (n = 162) 1.00 1.00 1.00 
1–2 (n = 441) 0.83 (0.45–1.52) 1.49 (0.80–2.78) 1.10 (0.70–1.73) 
3–4 (n = 300) 0.83 (0.41–1.68) 1.71 (0.87–3.38) 1.22 (0.74–2.02) 
5+ (n = 86) 0.96 (0.36–2.55) 1.02 (0.35–2.94) 0.95 (0.45–2.01) 
Chlamydia/gonorrhea positive 
No (n = 956) 1.00 1.00 1.00 
Yes (n = 33) 2.09 (0.84–5.18) 2.95 (1.43–6.10) 2.19 (1.15–4.16) 
“CI”: confidence interval; “HPV”: human papillomavirus; “N/A”: not applicable. 
a North America includes United States; Europe includes France, Germany, and Spain; Latin America includes Colombia; and Asia includes Philippines and 
Thailand.  
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consistent with age-specific prevalence data from a meta-analysis that 
showed considerable levels of infection with high-risk HPV types 
among women aged 25 years and older [23]. The meta-analysis also 
noted second peaks among women aged ≥45 years in Central and 
South America, southern Asia, and southern Europe. Although our trial 
also included women from these regions, prevalence data are available 
only through age 45, raising the question of whether a wider age range 
would have revealed second peaks similar to those observed in other 
studies. With respect to baseline infection with the five additional HPV 
types targeted by the 9vHPV vaccine (31/33/42/52/58), the 
prevalence of these infections in adult women was equal to, or slightly 
greater than, the prevalence of 4vHPV in all study regions. 
Our data also showed that the prevalence of infection with non- 
vaccine HPV types 35/39/51/56/59 was higher than the prevalence of 
4vHPV types and types 31/33/45/52/58. Previous reports have shown 
that the prevalence of HPV types 35/39/51/56/59 among women aged 
15 to 26 years was 19%, similar to the 17% we observed in women aged 
24 to 34 years [36]. However, although these non-vaccine types con-
tribute substantially to the burden of infection, they are not as prevalent 
in CIN2, CIN3, AIS, and invasive cervical cancer [36,37]. In fact, less 
than 7% of cervical cancers worldwide are attributed to HPV types 35/ 
39/51/56/59 [37]. 
Our findings suggest that factors associated with HPV infection in 
mid-adult women are similar to those in younger women, such as 
younger age, younger age at first intercourse, being single, current use 
of tobacco, and higher number of past and recent sex partners [38–40]. 
Many of the point estimates relating sexual behavior characteristics to 
incident HPV were not statistically significant, likely owing to the small 
numbers of incident cases in some strata. Nonetheless, the magnitude of 
the point estimates associated with these characteristics were often 
large, a finding that suggests sexual behaviors continue to confer risk of 
HPV infections among women beyond the age range that is typically 
targeted in HPV immunization programs. 
Several methodologic considerations warrant attention. Women in 
this trial were enrolled from primary care settings; more than 50% of 
the cohort had only one lifetime sex partner and more than 80% had 
three or fewer lifetime sex partners. The cohort is therefore not re-
presentative of women with a higher number of lifetime and recent 
sexual partners and less access to health care, groups that would be 
expected to have an even higher prevalence and incidence of HPV in-
fection. As such, the data presented here may be biased to a lower 
prevalence and rate of new incident and persistent anogenital HPV 
infections among mid-adult-aged women. Although the trial cohort was 
followed for 48 months, analyses of persistent infections were based on 
a subset of data from generally HPV-naive women in the placebo arm of 
the trial who developed incident infections. The limited number of at- 
risk women in these analyses resulted in a relatively small number of 
persistent infections. In addition, the HPV-naive group was likely at 
lower risk than women who had evidence of a current or prior HPV 
infection at baseline. 
This report also has several notable strengths. It addresses IARC's 
call for data on the natural history of HPV infection among older 
women, including data on persistent infection [22]. Results are drawn 
from a large, “average-risk” cohort of geographically diverse women. 
The size and global nature of the clinical trial from which data are 
drawn offer new insight, not only on regional differences in prevalence 
of high-risk HPV types, but also on how these infections are differen-
tially distributed between women aged 24 to 34 years and those aged 
35 to 45 years. The trial included repeated measures of HPV infection 
every 6 months over a period of 4 years, providing a robust dataset for 
this analysis. These data also provide insight on infection prevalence 
and incidence of five HPV types that are not currently included in any 
licensed vaccine. Although these non-vaccine HPV types had 
prevalence and incidence estimates similar to or higher than those of 
vaccine types, their combined relative contribution to high-grade cer-
vical lesions and cervical cancers is considerably lower than the seven 
high-risk types targeted by the 9vHPV vaccine [12,36,41]. 
Emerging real-world evidence demonstrates the benefit of HPV 
vaccination strategies that target multiple age cohorts and achieve high 
vaccine uptake [21]. In locations where vaccination strategies have 
Table 3 
Anogenital HPV incident infection rate and incident-persistent infection rate in women aged 24 to 45 years.         
HPV type HPV incident infection rate HPV incident-persistent infection rate 
N positive Person-years Incidence per 100 person-years 
(95% CI) 
N positive Person-years Incident-persistent infection per 
100 person-years (95% CI)  
6 38 3765.6 1.01 (0.72–1.38) 15 3802.9 0.39 (0.22–0.65) 
11 7 3809.9 0.18 (0.07–0.38) 2 3817.5 0.05 (0.01–0.19) 
16 57 3702.7 1.54 (1.17–1.99) 37 3755.5 0.99 (0.69–1.36) 
18 23 3773.1 0.61 (0.39–0.91) 12 3797.6 0.32 (0.16–0.55) 
31 18 3792.2 0.47 (0.28–0.75) 11 3804.7 0.29 (0.14–0.52) 
33 12 3798.5 0.32 (0.16–0.55) 3 3814.6 0.08 (0.02–0.23) 
35 18 3789.9 0.47 (0.28–0.75) 6 3810.9 0.16 (0.06–0.34) 
39 35 3753.6 0.93 (0.65–1.29) 16 3789.7 0.42 (0.24–0.68) 
45 20 3787.2 0.53 (0.32–0.81) 9 3808.0 0.24 (0.11–0.45) 
51 59 3719.4 1.59 (1.21–2.04) 27 3777.0 0.71 (0.47–1.04) 
52 35 3755.3 0.93 (0.65–1.29) 17 3790.6 0.45 (0.26–0.72) 
56 83 3679.9 2.26 (1.80–2.79) 31 3763.3 0.82 (0.56–1.17) 
58 28 3769.2 0.74 (0.49–1.07) 9 3802.2 0.24 (0.11–0.45) 
59 25 3780.2 0.66 (0.43–0.97) 12 3800.0 0.32 (0.16–0.55) 
6/11/16/18 111 3611.4 3.07 (2.54–3.69) 62 3720.4 1.67 (1.28–2.13) 
31/33/45/52/58 99 3636.5 2.72 (2.22–3.30) 45 3744.4 1.20 (0.88–1.60) 
35/39/51/56/59 166 3517.1 4.72 (4.04–5.47) 77 3687.0 2.09 (1.65–2.60) 
6/11/16/18/31/33/45/52/58 181 3464.7 5.22 (4.51–6.02) 98 3656.8 2.68 (2.18–3.26) 
16/18/31/33/45/52/58/35/39/51/ 
56/59 
266 3287.2 8.09 (7.18–9.08) 142 3571.4 3.98 (3.36–4.67) 
31/33/45/52/58 no 6/11/16/18 no 
35/39/51/56/59 
70 3680.8 1.90 (1.49–2.40) 33 3760.6 0.88 (0.60–1.23) 
6/11/16/18 no 31/33/45/52/58 no 
35/39/51/56/59 
87 3653.1 2.38 (1.91–2.93) 47 3742.6 1.26 (0.92–1.67) 
35/39/51/56/59 no 31/33/45/52/58 
no 6/11/16/18 
137 3577.2 3.83 (3.22–4.51) 59 3723.3 1.58 (1.21–2.04) 
“CI”: confidence interval; “HPV”: human papillomavirus.  
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Fig. 1. 48-month cumulative incidence Kaplan–Meier curves among women aged 24 to 45 years for (A) incident infection and (B) incident-persistent infection. 
“4vHPV”: quadrivalent human papillomavirus; “9vHPV”: 9-valent human papillomavirus. 
Fig. 2. Number of HPV types in anogenital infection among women ages 24 to 45 who had at least 1 of 12 measured high-risk HPV types. 
“HPV”: human papillomavirus. 
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included catch-up cohorts, such as older teens and young women, de-
clines in the prevalence of vaccine-type HPV infection, anogenital 
warts, and CIN2+ lesions have been observed [21]. This real-world 
evidence is based on more than 8 years of follow-up in vaccinated 
women in developed countries. As it takes decades for cervical cancer to 
develop, the population-level impact of HPV vaccination on CIN2+ is 
the most proximal outcome to cervical cancer, and is recognized as a 
valid proxy for vaccine effectiveness against cervical cancer by reg-
ulatory agencies worldwide [7,42–44]. However, vaccine impact and 
effectiveness data are not yet available for women who were vaccinated 
during their adult years. Given the favorable efficacy and im-
munobridging data from the 4vHPV and 9vHPV vaccine clinical pro-
grams, real-world impact and effectiveness in adult women can be ex-
pected as vaccine uptake in this age group increases and when sufficient 
follow up time is available. 
5. Conclusions 
Our findings suggest that women who are older than the age typi-
cally targeted by HPV vaccination programs are at risk for incident and 
incident-persistent HPV anogenital infections, depending on sexual 
behavior. Although most new HPV infections clear, some persist and 
can lead to cervical precancer and cancer if left untreated. In addition, 
most infections in this low-risk group of women are single-type HPV 
infections, suggesting that a sizable proportion of adult women remain 
susceptible to infections with other HPV types to which they may not 
have yet been exposed. Our data highlight the need for primary pre-
vention of HPV infection in at-risk adult women. This information can 
inform development or modification of HPV immunization programs 
and guidelines in a manner that is tailored to the needs of adult women, 
for whom few such guidelines currently exist. 
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